Iambic Therapeutics, Inc. Common Stock (NASDAQ:IAM)
| Market Cap | 223.22M+40.2% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 9.38M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,935,896 |
| Open | 19.31 |
| Previous Close | 18.91 |
| Day's Range | 19.31 - 25.00 |
| 52-Week Range | 16.15 - 25.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About IAM
Iambic Therapeutics, Inc. develops AI driven platform for drug discovery. It combines proprietary AI-driven platforms with the expertise of experienced drug discovery scientists to identify, design, and optimize novel therapeutic candidates across a range of disease areas. The company was founded by Thomas Miller and Fred Manby on October 14, 2019 and is headquartered in San Diego, CA.
$IAM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IAM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IAM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IAM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IAM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IAM from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in IAM
| ETF | Est. Holding Size |
|---|---|
| ARKGARK Genomic Revolution ETF | $22.41M |
| CANCTema Oncology ETF | $1.18M |
| HLTHTema Healthcare AI ETF | $206.36K |
Estimated from each fund’s disclosed top holdings × AUM
IAM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from IAM’s recent data — informational, not investment advice